Why the study?
Does celecoxib reduce the incidence of symptomatic ulcers and ulcer complications compared to standard NSAIDs in patients with osteoarthritis and rheumatoid arthritis?
Does celecoxib reduce the incidence of symptomatic ulcers and ulcer complications compared to standard NSAIDs in patients with osteoarthritis and rheumatoid arthritis?
Celecoxib at supratherapeutic doses is associated with lower upper gastrointestinal toxicity compared to standard-dose NSAIDs, particularly in patients not taking aspirin.
Answers are grounded in this paper and cite their sources.
Supports celecoxib over standard NSAIDs to reduce GI toxicity in arthritis; confirms RCT safety advantage.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Silverstein et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: